Trusted Resource for Clinical Trials, Protocols & Progress
US vs UK Recruitment Tactics That Actually Move Numbers US vs UK Recruitment Tactics That Actually Move Numbers (and Survive Inspection) Outcomes, not activity: the recruitment playbook that lifts randomizations on both sides of the Atlantic Why “more outreach” isn’t a strategy Recruitment fails when teams mistake volume for velocity. More emails, more postcards, more…
Read More “US vs UK Recruitment Tactics That Actually Move Numbers” »
IND Application Checklist: Modules, Forms, Timelines & Common Deficiencies IND Application Checklist: A US-First Guide to Modules, Forms, Timelines, and Fixing Common Pitfalls What an “inspection-ready” IND looks like—and why it matters for US/UK/EU sponsors Outcome definition: faster first-patient-in without regulatory rework An inspection-ready Investigational New Drug submission balances scientific credibility, procedural compliance, and operational…
Read More “IND Application Checklist: Modules, Forms, Timelines & Common Deficiencies” »
Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Predictable Outcomes (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…
Read More “Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)” »
Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations Enrollment Funnel Analytics: How to Find the Leaks and Lift Randomizations with a System You Can Defend Why enrollment funnels decide study success—and how analytics turns “maybe” into predictable randomizations From activity to outcomes: measuring the right moments in the funnel Every clinical program lives or dies…
Read More “Enrollment Funnel Analytics: Find the Leaks, Lift Randomizations” »
Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Avoidable Pitfalls (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…
Read More “Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)” »
Feasibility Questions That Predict Enrollment (Scoring Sheet) Feasibility Questions That Actually Predict Enrollment: A Defensible Scoring Sheet for US/UK/EU Programs Why feasibility must predict enrollment—not just describe the site—and how to make it inspection-ready From “profile of a site” to “probability of randomization” Traditional questionnaires catalog capabilities—beds, scanners, prior trials—but rarely answer the business-critical question:…
Read More “Feasibility Questions That Predict Enrollment (Scoring Sheet)” »
Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Avoidable Pitfalls (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…
Read More “Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)” »
Site Activation Checklist (US & UK): Docs, Timelines, Pitfalls Site Activation (US & UK): An Inspection-Ready Checklist of Documents, Timelines, and Pitfalls Outcome-first activation: open sites fast, safely, and in a way that survives FDA/MHRA scrutiny What “activation” must prove on day one Activation is not a flip of a calendar—it’s a verifiable condition set…
Read More “Site Activation Checklist (US & UK): Docs, Timelines, Pitfalls” »
Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C) From Pre-IND to IND: A US-First FDA Meeting Strategy with Reviewer-Ready Packages and Avoidable Pitfalls (Type B/C) Outcome-Oriented Game Plan: What “Good” Looks Like from Pre-IND to IND (US-First with EU/UK Mapping) Decisions before documents: frame the meeting around outcomes The most successful sponsors…
Read More “Pre-IND to IND: FDA Meeting Strategy, Packages & Pitfalls (Type B/C)” »
